Fulltext

A novel therapeutic option in Cogan diseases? TNF-α blockers

Fricker, M. ; Baumann, A. ; Wermelinger, F. ; Villiger, P. ; Helbling, A.

In: Rheumatology International, 2007, vol. 27, no. 5, p. 493-495

Aggiungi alla tua lista
    Titre
    • A novel therapeutic option in Cogan diseases? TNF-α blockers
    Auteur
    • Fricker, M.. Division of Allergology, Policlinics of Allergy and Immunology, Department of Rheumatology and Clinical Immunology/Allergology, University Hospital (Inselspital), 3010, Bern, Switzerland
    • Baumann, A.. Department of ENT and Head and Neck Surgery, University Hospital (Inselspital), 3010, Bern, Switzerland
    • Wermelinger, F.. Division of Allergology, Policlinics of Allergy and Immunology, Department of Rheumatology and Clinical Immunology/Allergology, University Hospital (Inselspital), 3010, Bern, Switzerland
    • Villiger, P.. Division of Allergology, Policlinics of Allergy and Immunology, Department of Rheumatology and Clinical Immunology/Allergology, University Hospital (Inselspital), 3010, Bern, Switzerland
    • Helbling, A.. Division of Allergology, Policlinics of Allergy and Immunology, Department of Rheumatology and Clinical Immunology/Allergology, University Hospital (Inselspital), 3010, Bern, Switzerland
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • Rheumatology International, 2007, vol. 27, no. 5, p. 493-495. Springer-Verlag
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:312127
    Summary
    Cogan's syndrome is characterized by non-infectious, interstitial keratitis combined with a vestibulo-auditory deficit. Despite therapy with corticosteroids in combination with immunosuppressive agents, relapses occurred in two subjects and the clinical course suggested a progression of the disease. Treatment with anti-TNF-α was started leading to a rapid and sustained clinical remission for over 2 respectively 3years